Quick orientationEvidence update: 6 October 2026
What is Semax?
Semax is a synthetic peptide developed from a fragment of ACTH and is discussed for attention, memory and neurological recovery.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Regional clinical research and preclinical studies explore stroke, cognition and stress; evidence outside those settings is limited.
What the mechanism suggests
ACTH(4–7)-derived synthetic peptide with proposed neurotrophic and neurotransmitter effects.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
ACTH(4–7)-derived synthetic peptide with proposed neurotrophic and neurotransmitter effects.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Human study deep dive
The most informative human evidence we could identify is translated below, with the original source linked.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
Semax during stroke rehabilitation — human study
Clinical rehabilitation study · 110 post-ischaemic-stroke patientsTwo 10-day courses at 6000 mcg/day, separated by 20 days, were associated with higher plasma BDNF and faster improvement in Barthel functional scores in the Semax groups.
There is condition-specific human work, but it is not evidence for everyday focus/nootropic use.
What it doesn't prove: Study design/reporting is not equivalent to a large modern placebo-controlled international RCT.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| Russian intranasal | 0.1% intranasal formulations are common in | Usually short courses | Protocol-specific | Human research / regional |
| research/product context | published Russian work | medicine | ||
| Retinal rehabilitation study | 0.1% Semax intranasal instillation in C comparison arm; endonasal electrophoresis in intervention arm | ourse treatment | Fixed formulation | Human clinical study |
| Higher-intensity neurological | Published/summarized Russian protocols use | ~5–10 days in acute | Indication-specific | Human research |
| protocols | substantially higher daily exposure than nootropic community use, including mg-range daily totals | neurological settings |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Low nootropic convention | ~200–300 mcg/day intranasal | ~10–14 days to several weeks | Usually fixed | Community |
| Common nootropic range | ~200–600 mcg/day intranasal, split 2–3 administrations | Short courses | Usually fixed | Community/specialist |
| Per-nostril specialist protocol | 300–600 mcg per nostril once or twice daily | ~10–14 days | Fixed | Specialist synthesis of Russian protocols |
| Prime Life progressive protocol | Progressive morning dosing over ~6–8 weeks | 6–8 weeks; similar washout claimed | Increase every ~2 weeks | Clinic/community; not established Russian licensed schedule |
Semax dosing is indication- and formulation-dependent. Acute Russian neurological protocols can be many times larger than Western nootropic schedules, so PP should not collapse them into a single 200–600 mcg figure.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Nootropic claims exceed the strongest clinical evidence.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
There is condition-specific human work, but it is not evidence for everyday focus/nootropic use.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.